BMS-688521是一种高效、口服活性的LFA-1/ICAM相互作用抑制剂，在细胞粘附试验和混合淋巴细胞反应（MLR）中的IC50值分别为2.5nM和60nM，在过敏性嗜酸性肺炎模型中展现出治疗潜力。
/
-25~-15℃避光保存，有效期3年。
[1] Watterson SH, Xiao Z, Dodd DS, Tortolani DR, Vaccaro W, Potin D, Launay M, Stetsko DK, Skala S, Davis PM, Lee D, Yang X, McIntyre KW, Balimane P, Patel K, Yang Z, Marathe P, Kadiyala P, Tebben AJ, Sheriff S, Chang CY, Ziemba T, Zhang H, Chen BC, DelMonte AJ, Aranibar N, McKinnon M, Barrish JC, Suchard SJ, Murali Dhar TG. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521). J Med Chem. 2010 May 13;53(9):3814-30. doi: 10.1021/jm100348u. PMID: 20405922.
